Fierce Pharma
JANUARY 31, 2024
More than two years after Aduhelm's controversial and ill-fated FDA accelerated approval, Bi | Biogen is discontinuing its first Alzheimer's disease therapy, Aduhelm, after walking a rocky path. The company is taking a $60 million charge, halting sales and terminating a confirmatory trial.
MedCity News
JANUARY 31, 2024
We and our collective organizations’ providers have treated 10,000’s of Americans, who suffer from obesity and/or Type 2 diabetes with GLP-1 drugs. And we believe we have important observations to share.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JANUARY 31, 2024
Beaten to the punch by Pfizer in developing a vaccine for COVID, GSK has regained some of its lost luster as a vaccine powerhouse with its advancement of respiratory syncytial virus (RSV) shot Arex | GSK's RSV vaccine Arexvy generated $1.5 billion in sales in 2023 compared to $890 million for Pfizer's Abrysvo. But the British pharma major says that the successful launch represents just one round of a boxing match, and much is still to be decided, especially with Moderna expected to joi
MedCity News
JANUARY 31, 2024
Biogen has returned its Aduhelm rights to Neurimmune, the company that initially developed the antibody Alzheimer’s disease drug. But Biogen isn’t abandoning Alzheimer’s, and its pipeline includes drugs that take other approaches to the neurodegenerative disorder.
Fierce Pharma
JANUARY 31, 2024
After charting a series of sales increases in 2023, Teva’s largely made good on the promise of its new CEO’s “Pivot to Growth” campaign. | After charting a series of sales increases in 2023, Teva’s largely made good on the promise of its new CEO’s “Pivot to Growth” campaign. With group revenues on the up-and-up, it’s all about maintaining momentum in the years to come, the company’s chief executive Richard Francis said in an interview.
PharmaVoice
JANUARY 31, 2024
The president of L.A.’s City of Hope Cancer Center believes the current state of cancer treatments can be greatly improved with a peek into the gut’s many mysteries.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
JANUARY 31, 2024
Point-of-care lung ultrasound – also known as lung POCUS – is a safer, more reliable alternative to X-ray in diagnosing pneumonia that provides information quickly. Yet it’s not widely considered the standard of care.
Fierce Pharma
JANUARY 31, 2024
AstraZeneca-partnered Enhertu has become a bright spot in Daiichi Sankyo’s business, and the Japanese pharma has again increased its sales projection for the HER2-directed antibody-drug conjugate.< | AstraZeneca-partnered Enhertu has become a bright spot in Daiichi Sankyo’s business, and the Japanese pharma keeps increasing its sales projections for the HER2-directed antibody-drug conjugate.
MedCity News
JANUARY 31, 2024
To succeed in ACO Reach, groups need to accurately identify the social determinants of health (SDoH) barriers affecting their patient population and determine which barriers could be addressed effectively. Some technology can accurately note specific SDoH risk factors facing a given patient and offer targeted intervention recommendations based on that patient’s unique SDoH risk factors.
Fierce Pharma
JANUARY 31, 2024
Even though Novartis grew sales and profits in the last quarter of 2023, the magnitude of the increases was not satisfactory to the Swiss pharma's investors. | Novartis grew sales and profits in the last quarter of 2023, but the magnitude of the increases was not satisfactory to the company’s investors. Among a portfolio of newer medicines, radiotherapy Pluvicto stuck out as a major drag.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmaTech
JANUARY 31, 2024
This article introduces that the basic technique for tolerance interval is implemented using the conventional range 85–115% LC where the proposed range in the PF is not taken into account.
pharmaphorum
JANUARY 31, 2024
Novartis ends development of Tim3 antibody sabatolimab in myelodysplastic syndromes after failed phase 3 trial.
MedCity News
JANUARY 31, 2024
Being Health, a startup that launched last week, offers a care team that includes psychiatrists, psychotherapists, nurse anesthetists, functional medicine physicians, nutritionists, acupuncturists and care advocates. It serves patients both virtually and in person.
pharmaphorum
JANUARY 31, 2024
A surge in 2023 sales and profits fuelled by diabetes and obesity drugs has driven Novo Nordisk's valuation toward $500bn
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
ALULA
JANUARY 31, 2024
This Black History Month, we celebrate African culture & history via Benjamin Banneker and Madam C. J. Walker for maintaining and pursuing a clear vision.
Pharmaceutical Technology
JANUARY 31, 2024
CMS’ CGT Access Model will see allow the agency to negotiate negotiate pricing and build a framework that expands access to treatments.
ALULA
JANUARY 31, 2024
African culture and history offer wisdom for the world. This Black History Month, we celebrate powerful leaders who achieved lasting positive impact.
MedCity News
JANUARY 31, 2024
Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
ALULA
JANUARY 31, 2024
This Black History Month, we celebrate African culture & history via Althea Neale Gibson and Berry Gordy Jr for being great leaders by coaching others.
pharmaphorum
JANUARY 31, 2024
AbbVie’s CD20xCD3 bispecific antibody Tepkinly has been recommended by NICE for NHS use as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an aggressive and fast-growing form of non-Hodgkin lymphoma. Tepkinly (epcoritamab) – the first medicine to emerge from AbbVie’s $3.9 billion alliance with Genmab signed in 2020 – can be used to treat adults with DLBCL whose cancer has returned or has not responded to at least two previous systemic treatments.
PharmaTech
JANUARY 31, 2024
The emergence of mRNA vaccines and cell and gene therapies have pushed innovation in analytical methods.
pharmaphorum
JANUARY 31, 2024
Digital health investments has halved for the second year in a row, according to a new report from CB Insights
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
PharmaTimes
JANUARY 31, 2024
Over 10,000 pharmacies in England will be offering the new advanced service
pharmaphorum
JANUARY 31, 2024
GSK's RSV vaccine Arexvy outsold Pfizer's Abrysvo last year, but fourth-quarter figures suggest the gap may be narrowing.
PharmaTech
JANUARY 31, 2024
Effective analytics will eliminate failures, deviations, and non-conformances.
PharmaTimes
JANUARY 31, 2024
The institute is one of two UK laboratories wholly funded by the MRC
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
PharmaTech
JANUARY 31, 2024
Distek’s software update for the Opt-Diss–In-Situ Fiber Optic UV System for Dissolution Testing, Version 3.20, introduces enhancements designed to streamline the dissolution testing process and expand the system’s capabilities.
PharmExec
JANUARY 31, 2024
Aduhelm (aducanumab-avwa) was granted accelerated approval by the FDA in June 2021 despite misgivings from the agency's Peripheral and Central Nervous System Drugs Advisory Committee.
PharmaTech
JANUARY 31, 2024
Designed for processing high viscosity dispersions and suspensions, the ROSS line of Dual-Shaft Mixers are versatile systems utilized in the chemical, pharmaceutical, food, cosmetic, adhesive, coating, composite, and other industries.
Pharmaceutical Commerce
JANUARY 31, 2024
FDA to evaluate Darzalex Faspro with bortezomib, lenalidomide, and dexamethasone for induction and consolidation treatment and with lenalidomide for the maintenance treatment of adults newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
307 
Let's personalize your content